drug · small molecule
neratinib
Marketedupdated 3mo agoby $PBYI PUMA BIOTECHNOLOGY, INC.🔗 ChEMBL
Approvedcommunity read0 votes
Small molecule drug with a maximum clinical stage of Approval (across all indications), with an approval for neoplasm and 8 investigational indications.
targets
Epidermal growth factor receptorReceptor tyrosine-protein kinase erbB-2Receptor tyrosine-protein kinase erbB-4
all catalysts(0)
nothing on the calendar yet
Trials studying neratinib
- phase2Neoadjuvant Neratinib in Stage I-III HER2-Mutated Lobular Breast Cancers
- phase2Neratinib + Valproate in Advanced Solid Tumors, w/Expansion Cohort in Ras-Mutated Ca
- phase2Capecitabine 7/7 Schedule With Neratinib in Patients With Metastatic HER2-Positive Breast Cancer
- phase2Trial of Pre-operative Neratinib and Endocrine Therapy With Trastuzumab in ER-Positive, HER-2 Positive Breast Cancers
- phase2Neratinib In Combination With Chemotherapy/Trastuzumab/Pembrolizumab In HER2 Gastroesophageal Cancer
- phase2Neratinib +/- Fulvestrant in HER2+, ER+ Metastatic Breast Cancer
- phase2Innovative Trial for Understanding the Impact of Targeted Therapies in NF2-Related Schwannomatosis (INTUITT-NF2)
- phase2INdividualized Screening Trial of Innovative Glioblastoma Therapy (INSIGhT)
Patent cliff
source: FDA Orange Bookfirst barrier falls
Oct 15, 2028
~2.2 years out
Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.
patents (9)
- Jul 18, 2031method-of-use (U-3047)US 86692734.9y
- Dec 29, 2030compositionUS 73998654.4y
- Nov 20, 2030formulationUS 85184464.3y
- Nov 5, 2030formulationUS 87907084.2y
- Mar 24, 2030method-of-use (U-3097)US 92112913.6y
- Aug 4, 2029method-of-use (U-3047)US 92657843.0y
- Oct 15, 2028method-of-use (U-3097)US 100357882.2y
- Oct 15, 2028method-of-use (U-2043)US 91395582.2y
- Oct 15, 2028method-of-use (U-3097)US 96309462.2y
News(1)
- Post–T-DXd Sacituzumab Govitecan Plus Trastuzumab Yields Low ORR in HER2+ Metastatic Breast CancerSacituzumab govitecan plus trastuzumab following T-DXd did not meet the primary end point of the SATEEN trial in HER2+ metastatic breast cancer.onclive · 3mo ago
Data sources
last refreshed 9m ago
Found something off?
comments(0)
5-min edit window · permanent after that